Ultragenyx has finalized its rolling biologics license application (BLA) submission to the FDA for DTX401, its adeno-associated virus (AAV) gene therapy candidate targeting glycogen storage disease type Ia (GSDIa). The submission encompasses all five modules, including preclinical toxicology reports, chemistry, manufacturing and control (CMC) data supporting a scalable, single-dose intravenous vector, and interim clinical safety and efficacy data from its Phase I/II trial. In that trial, 12 patients achieved a mean 80% reduction in fasting blood lactate levels and maintained normal glucose homeostasis for up to 18 months post infusion. This application positions DTX401 to become the first approved gene therapy for GSDIa, a rare metabolic disorder affecting approximately 1,200 patients in the U.S. and Europe combined.

Shares of Ultragenyx surged 15.5% on the day the company announced the completion of its rolling submission, driven by a 60% increase in trading volume compared with its 90-day average. Institutional investors accounted for nearly 70% of the volume, according to market data, suggesting strong conviction among hedge funds and biotech-focused mutual funds. Retail participation also ticked higher, as indicated by a 25% rise in small-lot trades. This price action reflects heightened investor confidence in the regulatory pathway for DTX401 and the potential for a late-stage catalyst in the current quarter.

Despite the recent rally, consensus earnings estimate revisions over the past four weeks have been modestly negative. Of the eight analysts covering Ultragenyx, five have trimmed their 2026 revenue forecasts by an average of 4%, citing conservative launch assumptions and potential manufacturing scale-up delays. However, three have maintained or raised estimates, pointing to DTX401 peak sales projections of $450 million annually by 2030 and upside from pipeline programs in hemophilia A and sickle cell disease. The weighted average price target stands at $135, implying limited upside from current levels but reflecting a balanced view of near-term regulatory milestones and longer-term commercial execution risks.